RecruitingPHASE1, PHASE2NCT06874010
A Multiple Ascending Dose Study of DT-216P2 in Patients With Friedreich's Ataxia
Studying Friedreich ataxia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Design Therapeutics, Inc.
- Intervention
- DT-216P2(drug)
- Enrollment
- 20 enrolled
- Eligibility
- 18-65 years · All sexes
- Timeline
- 2025 – 2027
Study locations (3)
- Scientia Clinical Research Ltd, Sydney, New South Wales, Australia
- Doherty Clinical Trials, East Melbourne, Victoria, Australia
- Nucleus Network, Melbourne, Victoria, Australia
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06874010 on ClinicalTrials.govOther trials for Friedreich ataxia
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT06628687A Study to Learn How BIIB141 (Omaveloxolone) Affects the Health of Participants With Friedrich's Ataxia Who Took it During Pregnancy and/or During Breastfeeding and About the Health of Their BabiesBiogen
- RECRUITINGNCT06865482Clinical Course Of Disease In Participants With FA-CMLexeo Therapeutics
- RECRUITINGPHASE3NCT06953583A Study to Learn More About the Effects and Long-Term Safety of BIIB141 (Omaveloxolone) in Participants With Friedreich's Ataxia Aged 2 to 15 Years Old (BRAVE)Biogen
- RECRUITINGNCT07013292Efficacy of Omaveloxolone Treatment for Dysphagia in French Patients With Friedreich's AtaxiaCentre Hospitalier Universitaire de Nice
- RECRUITINGNANCT06692296Efficacy of Stabilometric Platform to Improve Standing Balance in Patients With Friedreich's AtaxiaIRCCS Eugenio Medea
- RECRUITINGNCT06623890A Study to Learn More About the Long-Term Safety of BIIB141 (Omaveloxolone) in Participants With Friedreich's Ataxia Who Are Prescribed it by Their Own DoctorsBiogen
- RECRUITINGPHASE1NCT06054893A Study to Find Out How BIIB141 (Omaveloxolone) is Processed in the Body and to Learn More About Its Safety in Participants With Friedreich's Ataxia Aged 2 to 15 Years OldBiogen
- RECRUITINGPHASE2NCT06447025An Open-Label Study of CTI-1601 in Subjects With Friedreich's AtaxiaLarimar Therapeutics, Inc.